VRTX Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of 34.76% compared to Vertex Pharmaceuticals, Inc.'s net margin of 33.55%. Vertex Pharmaceuticals, Inc.'s return on equity of 22.13% beat Amgen, Inc.'s return on equity of 95.55%.

Vertex Pharmaceuticals, Inc. has a consensus price target of $485.36, signalling upside risk potential of 4.8%. On the other hand Amgen, Inc. has an analysts' consensus of $324.25 which suggests that it could fall by -4.68%. Given that Vertex Pharmaceuticals, Inc. has higher upside potential than Amgen, Inc., analysts believe Vertex Pharmaceuticals, Inc. is more attractive than Amgen, Inc..

Vertex Pharmaceuticals, Inc. has a beta of 0.318, which suggesting that the stock is 68.249% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.

Vertex Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.8% to investors and pays a quarterly dividend of $2.38 per share. Vertex Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.

Vertex Pharmaceuticals, Inc. quarterly revenues are $3.1B, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Vertex Pharmaceuticals, Inc.'s net income of $1.1B is lower than Amgen, Inc.'s net income of $3.2B. Notably, Vertex Pharmaceuticals, Inc.'s price-to-earnings ratio is 32.64x while Amgen, Inc.'s PE ratio is 26.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals, Inc. is 10.23x versus 5.13x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

IDEXX Laboratories, Inc. has a net margin of 34.76% compared to Vertex Pharmaceuticals, Inc.'s net margin of 24.85%. Vertex Pharmaceuticals, Inc.'s return on equity of 22.13% beat IDEXX Laboratories, Inc.'s return on equity of 66.88%.

Vertex Pharmaceuticals, Inc. has a consensus price target of $485.36, signalling upside risk potential of 4.8%. On the other hand IDEXX Laboratories, Inc. has an analysts' consensus of $759.00 which suggests that it could grow by 4.56%. Given that Vertex Pharmaceuticals, Inc. has higher upside potential than IDEXX Laboratories, Inc., analysts believe Vertex Pharmaceuticals, Inc. is more attractive than IDEXX Laboratories, Inc..

Vertex Pharmaceuticals, Inc. has a beta of 0.318, which suggesting that the stock is 68.249% less volatile than S&P 500. In comparison IDEXX Laboratories, Inc. has a beta of 1.668, suggesting its more volatile than the S&P 500 by 66.77%.

Vertex Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IDEXX Laboratories, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vertex Pharmaceuticals, Inc. pays -- of its earnings as a dividend. IDEXX Laboratories, Inc. pays out -- of its earnings as a dividend.

Vertex Pharmaceuticals, Inc. quarterly revenues are $3.1B, which are larger than IDEXX Laboratories, Inc. quarterly revenues of $1.1B. Vertex Pharmaceuticals, Inc.'s net income of $1.1B is higher than IDEXX Laboratories, Inc.'s net income of $274.6M. Notably, Vertex Pharmaceuticals, Inc.'s price-to-earnings ratio is 32.64x while IDEXX Laboratories, Inc.'s PE ratio is 57.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals, Inc. is 10.23x versus 14.20x for IDEXX Laboratories, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 34.76% compared to Vertex Pharmaceuticals, Inc.'s net margin of 31.72%. Vertex Pharmaceuticals, Inc.'s return on equity of 22.13% beat Eli Lilly & Co.'s return on equity of 106.26%.

Vertex Pharmaceuticals, Inc. has a consensus price target of $485.36, signalling upside risk potential of 4.8%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,045.59 which suggests that it could grow by 1.16%. Given that Vertex Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Vertex Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Vertex Pharmaceuticals, Inc. has a beta of 0.318, which suggesting that the stock is 68.249% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Vertex Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Vertex Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vertex Pharmaceuticals, Inc. quarterly revenues are $3.1B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Vertex Pharmaceuticals, Inc.'s net income of $1.1B is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Vertex Pharmaceuticals, Inc.'s price-to-earnings ratio is 32.64x while Eli Lilly & Co.'s PE ratio is 51.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals, Inc. is 10.23x versus 15.86x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 34.76% compared to Vertex Pharmaceuticals, Inc.'s net margin of 21.32%. Vertex Pharmaceuticals, Inc.'s return on equity of 22.13% beat Pfizer Inc.'s return on equity of 10.84%.

Vertex Pharmaceuticals, Inc. has a consensus price target of $485.36, signalling upside risk potential of 4.8%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Pfizer Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Pfizer Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Vertex Pharmaceuticals, Inc. has a beta of 0.318, which suggesting that the stock is 68.249% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Vertex Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. Vertex Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Vertex Pharmaceuticals, Inc. quarterly revenues are $3.1B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Vertex Pharmaceuticals, Inc.'s net income of $1.1B is lower than Pfizer Inc.'s net income of $3.6B. Notably, Vertex Pharmaceuticals, Inc.'s price-to-earnings ratio is 32.64x while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals, Inc. is 10.23x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.